Dr. Lal Path Labs Ltd.

12%

o revising/updating them publicly. Classification: Restricted 3 Dr. Lal PathLabs – At a Glance 12% 3 Year Revenue CAGR 35% ROCE Excl. Cash & Investments 240% Dividend for FY23-24 4,857#

35%

blicly. Classification: Restricted 3 Dr. Lal PathLabs – At a Glance 12% 3 Year Revenue CAGR 35% ROCE Excl. Cash & Investments 240% Dividend for FY23-24 4,857# Pathology & Radiology test

240%

3 Dr. Lal PathLabs – At a Glance 12% 3 Year Revenue CAGR 35% ROCE Excl. Cash & Investments 240% Dividend for FY23-24 4,857# Pathology & Radiology tests; Comprehensive Test menu 280 Lab

10.7%

6 NABL accredited Labs; 2 CAP accredited Labs 4 Q3 FY25 Performance Overview Q3 FY25 Q3 FY24 10.7% Rs. 597 crore Revenue Rs. 539 crore 9.6% Rs. 154 crore EBITDA Rs. 141 crore 19.3% Rs. 98 c

Rs. 597 crore

accredited Labs; 2 CAP accredited Labs 4 Q3 FY25 Performance Overview Q3 FY25 Q3 FY24 10.7% Rs. 597 crore Revenue Rs. 539 crore 9.6% Rs. 154 crore EBITDA Rs. 141 crore 19.3% Rs. 98 crore PAT Rs.

Rs. 539 crore

accredited Labs 4 Q3 FY25 Performance Overview Q3 FY25 Q3 FY24 10.7% Rs. 597 crore Revenue Rs. 539 crore 9.6% Rs. 154 crore EBITDA Rs. 141 crore 19.3% Rs. 98 crore PAT Rs. 82 crore 10.3% 3.8% +

9.6%

s 4 Q3 FY25 Performance Overview Q3 FY25 Q3 FY24 10.7% Rs. 597 crore Revenue Rs. 539 crore 9.6% Rs. 154 crore EBITDA Rs. 141 crore 19.3% Rs. 98 crore PAT Rs. 82 crore 10.3% 3.8% +3% 20

Rs. 154 crore

Q3 FY25 Performance Overview Q3 FY25 Q3 FY24 10.7% Rs. 597 crore Revenue Rs. 539 crore 9.6% Rs. 154 crore EBITDA Rs. 141 crore 19.3% Rs. 98 crore PAT Rs. 82 crore 10.3% 3.8% +3% 20.6 Mn 6.9 Mn

Rs. 141 crore

rview Q3 FY25 Q3 FY24 10.7% Rs. 597 crore Revenue Rs. 539 crore 9.6% Rs. 154 crore EBITDA Rs. 141 crore 19.3% Rs. 98 crore PAT Rs. 82 crore 10.3% 3.8% +3% 20.6 Mn 6.9 Mn 23% Samples Patients

19.3%

Q3 FY24 10.7% Rs. 597 crore Revenue Rs. 539 crore 9.6% Rs. 154 crore EBITDA Rs. 141 crore 19.3% Rs. 98 crore PAT Rs. 82 crore 10.3% 3.8% +3% 20.6 Mn 6.9 Mn 23% Samples Patients Swasth

Rs. 98 crore

4 10.7% Rs. 597 crore Revenue Rs. 539 crore 9.6% Rs. 154 crore EBITDA Rs. 141 crore 19.3% Rs. 98 crore PAT Rs. 82 crore 10.3% 3.8% +3% 20.6 Mn 6.9 Mn 23% Samples Patients SwasthFit Contribut

Rs. 82 crore

rore Revenue Rs. 539 crore 9.6% Rs. 154 crore EBITDA Rs. 141 crore 19.3% Rs. 98 crore PAT Rs. 82 crore 10.3% 3.8% +3% 20.6 Mn 6.9 Mn 23% Samples Patients SwasthFit Contribution 18.6 Mn 6.7 M

“99% of participants responded that they were guided enough during OJT through guidance, feedback, monitoring and follow-ups by the training centre Representatives.”

Managing Director said

1

Chief Executive Officer said

1

Managing Director said

“We continue to drive growth through strategic expansion and deeper market penetration. While we have not taken any price hikes in nearly 2 years, sample growth is fueled by higher testing per patient and the strong momentum of SwasthFit, particularly in underserved towns and cities. Our franchise network is expanding, with each lab now servicing a larger number of collection centers. In North and East India, our cluster-based approach is accelerating growth in Tier 3 & 4 cities, while in the West, Suburban Diagnostics is gaining traction. In South and West India, we are also strengthening infrastructure and brand communication to boost sample volumes. We are focusing investments in frontline capabilities to enhance B2B outcomes. With a strong brand, growing bundled offerings, and a commitment to accessibility, we are well-positioned for sustained growth and leadership in the industry.” Commenting on the performance, Mr. Shankha Banerjee,

Chief Executive Officer said

“We delivered strong financial results in the third quarter of fiscal year 2025, with 10.7% revenue growth and 19.3% increase in profit after tax. Our focus on operational excellence, coupled with proactive initiatives on visibility and brand, contributed significantly to enhanced profitability while maintaining competitive pricing. Sample volumes grew by 10.3% Y-o-Y, with a patient growth of 3.8%. We are accelerating our reach with the planned opening of 15-20 new labs in this financial year. We are expanding our reach into Tier 3 and Tier 4 markets while strengthening our presence in the Core regions. We are making investments in new infrastructure in Metro / Tier 1 cities as well. Our focus on innovation, including new bundled test packages and the expansion of high-end and super- specialty tests, will continue to drive growth and enhance patient experience. Our robust digital infrastructure will play a crucial role in supporting this growth by providing seamless access and personal